157 related articles for article (PubMed ID: 34549487)
1. Debulking followed by intralesional 5-fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis.
Hamad J; Jolly PS
Dermatol Ther; 2021 Nov; 34(6):e15139. PubMed ID: 34549487
[TBL] [Abstract][Full Text] [Related]
2. Intralesional 5-Fluorouracil for Treatment of Non-Melanoma Skin Cancer: A Systematic Review.
Maghfour J; Kuraitis D; Murina A
J Drugs Dermatol; 2021 Feb; 20(2):192-198. PubMed ID: 33538569
[TBL] [Abstract][Full Text] [Related]
3. Intralesional therapy for the treatment of keratoacanthoma.
Kiss N; Avci P; Bánvölgyi A; Lőrincz K; Szakonyi J; Gyöngyösi N; Fésűs L; Lee G; Wikonkál N
Dermatol Ther; 2019 May; 32(3):e12872. PubMed ID: 30866135
[TBL] [Abstract][Full Text] [Related]
4. Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
Que SKT; Compton LA; Schmults CD
J Am Acad Dermatol; 2019 Jul; 81(1):111-122. PubMed ID: 31103317
[TBL] [Abstract][Full Text] [Related]
5. Aberrant p16, p53 and Ki-67 immunohistochemistry staining patterns can distinguish solitary keratoacanthoma from cutaneous squamous cell carcinoma.
Carr RA; Mesiano D; Heffron C; Radonic T; Wiggins J; Tso S; Agrawal R; Cheung E; Slater DN; Nichols L; Craig P
Pathology; 2023 Oct; 55(6):772-784. PubMed ID: 37573161
[TBL] [Abstract][Full Text] [Related]
6. Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series.
Marka A; Rodgers D; Zelaya Castillo L; Hoyt B; Chapman M; Carter J
J Drugs Dermatol; 2023 May; 22(5):507-508. PubMed ID: 37133471
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology.
Veenstra J; Ozog D; Loveless I; Adrianto I; Dimitrion P; Subedi K; Friedman BJ; Zhou L; Mi QS
J Invest Dermatol; 2023 Dec; 143(12):2397-2407.e8. PubMed ID: 37419445
[TBL] [Abstract][Full Text] [Related]
8. Intralesional 5-fluorouracil as a management for cutaneous squamous cell carcinomas: A rural Australian retrospective case series.
Luu W; McRae MY
Australas J Dermatol; 2023 Nov; 64(4):556-559. PubMed ID: 37665127
[TBL] [Abstract][Full Text] [Related]
9. Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors.
Ogita A; Ansai SI; Misago N; Anan T; Fukumoto T; Saeki H
J Dermatol; 2016 Nov; 43(11):1321-1331. PubMed ID: 27076258
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature.
Doerfler L; Hanke CW
J Drugs Dermatol; 2019 Jul; 18(7):693-696. PubMed ID: 31334929
[TBL] [Abstract][Full Text] [Related]
11. Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil.
Morse LG; Kendrick C; Hooper D; Ward H; Parry E
Dermatol Surg; 2003 Nov; 29(11):1150-3; discussion 1153. PubMed ID: 14641346
[TBL] [Abstract][Full Text] [Related]
12. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma.
Goldenhersh MA; Olsen TG
J Am Acad Dermatol; 1984 Feb; 10(2 Pt 2):372-8. PubMed ID: 6368620
[TBL] [Abstract][Full Text] [Related]
13. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
Cabibi D; Aragona F; Guarnotta C; Rodolico V; Zerilli M; Belmonte B; Schillaci L; Aragona F
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
[TBL] [Abstract][Full Text] [Related]
14. Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.
Fan X; Niu X; Wu Z; Yao L; Chen S; Wan W; Huang B; Qi RQ; Zhang T
Biomed Res Int; 2022; 2022():3168503. PubMed ID: 36051475
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
16. A clinical and biological review of keratoacanthoma.
Tisack A; Fotouhi A; Fidai C; Friedman BJ; Ozog D; Veenstra J
Br J Dermatol; 2021 Sep; 185(3):487-498. PubMed ID: 33864244
[TBL] [Abstract][Full Text] [Related]
17. To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma.
Poole M; Schwartz RA; Lambert WC; Alhatem A
Arch Dermatol Res; 2023 May; 315(4):903-915. PubMed ID: 36394634
[TBL] [Abstract][Full Text] [Related]
18. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons.
Chitwood K; Etzkorn J; Cohen G
Dermatol Surg; 2013 Sep; 39(9):1306-16. PubMed ID: 23915332
[TBL] [Abstract][Full Text] [Related]
19. Low detection rate of human papillomavirus in patients with cutaneous squamous cell carcinoma and keratoacanthoma.
Baek YS; Kim YC; Kim KE; Jeon J; Kim A; Song HJ; Kim C
Eur J Dermatol; 2022 Sep; 32(5):577-583. PubMed ID: 36468731
[TBL] [Abstract][Full Text] [Related]
20. Management of Keratoacanthoma: 157 Tumors Treated With Surgery or Intralesional Methotrexate.
Moss M; Weber E; Hoverson K; Montemarano AD
Dermatol Surg; 2019 Jul; 45(7):877-883. PubMed ID: 30608293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
